Future of Pharma

Regular price €64.99
A01=Brian D. Smith
adaptive organisations
Author_Brian D. Smith
Bayer Schering Pharma
big
Big Pharma
Boehringer Ingelheim
business
Business Models
Category=AK
Category=KJC
Category=KJK
Category=KJS
Category=KND
companies
Confer
Core Capabilities
criteria
D Tr
Development Productivity
Directional Policy Matrix
Distinctive Competencies
Dynamic Capabilities
eq_art-fashion-photography
eq_bestseller
eq_business-finance-law
eq_isMigrated=1
eq_isMigrated=2
eq_nobargain
eq_non-fiction
fitness
Fitness Criteria
Fitness Landscape
healthcare market trends
institutional healthcare systems
landscape
Management Science
Manager Business Model
Marketing Due Diligence
models
Multiple Business Model
organizational
Organizational Routines
Pharma Companies
Pharma Industry
pharmaceutical
Pharmaceutical Business Models
pharmaceutical industry evolution analysis
pharmaceutical innovation
Punctuated Equilibrium
routines
Speciality Pharma
supply chain optimisation
therapeutic development strategies
Trust Manager Model
Wo

Product details

  • ISBN 9781138247499
  • Weight: 453g
  • Dimensions: 174 x 246mm
  • Publication Date: 03 Oct 2016
  • Publisher: Taylor & Francis Ltd
  • Publication City/Country: GB
  • Product Form: Paperback
Delivery/Collection within 10-20 working days

Our Delivery Time Frames Explained
2-4 Working Days: Available in-stock

10-20 Working Days: On Backorder

Will Deliver When Available: On Pre-Order or Reprinting

We ship your order once all items have arrived at our warehouse and are processed. Need those 2-4 day shipping items sooner? Just place a separate order for them!

By any standard, the pharmaceutical industry's history has been a successful one. In addition to its profits and shareholder dividends, it has been seen by investors as relatively low risk and, largely, counter-cyclical to stock market trends. However, that important contribution appears to be petering out, with significant global implications for employees, shareholders, governments and patients. This is not just caused by the economic crisis. Long before this, several distinct but related streams of evidence emerged that now point to the stalling of the pharmaceutical industry. The Future of Pharma examines the causes of the industry's potential decline and offers a convincing and rigorous analysis of the options open to it. What emerges is a landscape defined, on the one hand, by the changing marketplace of mass-market consumers, institutional healthcare systems and wealthy individuals; and on the other by the alternate sources of commercial value - innovative therapies; super-efficient processes, supply chains and operations; and closer customer relations and increasingly tailored health services. The challenges to the pharmaceutical industry now and in the medium and long-term are very significant. Brian Smith's highly readable research findings are a wake-up call and a first step forward for anyone concerned with the future of the industry; whether executive, customer, policymaker or investor.
Professor Brian D. Smith began his career as a research chemist in a pharmaceutical R&D lab and then spent 20 years in technical and marketing roles before becoming an academic, author and adviser. Working at OUBS and SDA Bocconi, two of Europe's leading business schools, his research focuses on strategy creation and implementation in pharmaceutical and medical technology markets. Brian also runs a specialist consultancy that advises many of the world's largest companies in this sector. He is editor of the Journal of Medical Marketing, has written and co-written three major books and published many practitioner articles all of which can be seen at www.pragmedic.com